search
Back to results

ONLOOP Trial: Evaluating a New Surveillance and Support System for Survivors of Childhood Cancer in Ontario

Primary Purpose

Survivorship, Cancer, Heart Diseases

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
ONLOOP program
Sponsored by
The Hospital for Sick Children
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Survivorship focused on measuring Surveillance, Guideline-recommended surveillance, Implementation science, Reminder system, Intervention

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Survivors of childhood cancer who are currently aged 18 and older Diagnosed with cancer before age 18 between 1986-2017 At least 5 years from most recent childhood cancer event (latest of primary diagnosis, relapse, or second cancer before age 18) Treated at one of Ontario's five specialized childhood cancer programs Received radiation and/or anthracycline treatment that increased the survivor's risk of cardiomyopathy, breast cancer, and/or colorectal cancer Overdue for guideline-recommended surveillance by ≥6 months (mammogram and breast MRI, colonoscopy, and/or echocardiogram) Exclusion Criteria: Was not diagnosed or was not fully treated at one of Ontario's five pediatric cancer centres Developed a second cancer or relapse of their primary cancer after age 18 Not currently living in Ontario or address deemed ineligible by Ontario Health Opted out of a similar Ontario Health program (eg, the Ontario Breast Screening Program) Previously opted out of receiving invitations for Ontario Health research studies or similar communications

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Other

    Arm Label

    Intervention

    Delayed Intervention

    Arm Description

    Usual care plus ONLOOP program materials: Study invitation letter and invitation reminder 5 weeks later For those who sign up: receipt of a personalized health toolkit and then a screening reminder 6 months later Engagement of primary care provider through an introductory letter and then a reminder letter sent 6 months later

    Survivors will receive usual care for 13 months after study invitation packages are mailed out to the intervention arm. At that point, survivors in this group will also receive the study invitation package.

    Outcomes

    Primary Outcome Measures

    Completion of guideline-recommended surveillance tests
    Proportion of survivors who complete one or more of the guideline-recommended cardiac, breast or colon surveillance tests (echocardiography, mammogram and breast MRI, colonoscopy) during the 12 months after study cohort randomization

    Secondary Outcome Measures

    Completion of guideline-recommended surveillance tests
    Proportion of survivors who complete one or more of the guideline-recommended cardiac, breast or colon surveillance tests (echocardiography, mammogram and breast MRI, colonoscopy) during the 24 months after study cohort randomization
    Completion of each type of surveillance test
    Proportion of survivors who complete each type of surveillance test (among those eligible for the test)
    Completion of all guideline-recommended surveillance tests
    Proportion of survivors who are fully up-to-date according to surveillance guidelines
    Visits to primary care professionals and cancer specialists
    Number of outpatient visits to primary care professionals and to cancer specialists
    Use of other healthcare services
    Rates of emergency department visits and/or hospitalizations to understand impact on health system resources

    Full Information

    First Posted
    April 14, 2023
    Last Updated
    April 14, 2023
    Sponsor
    The Hospital for Sick Children
    Collaborators
    Women's College Hospital, Ottawa Hospital Research Institute
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05832138
    Brief Title
    ONLOOP Trial: Evaluating a New Surveillance and Support System for Survivors of Childhood Cancer in Ontario
    Official Title
    ONLOOP Trial: Evaluating a New Surveillance and Support System for Survivors of Childhood Cancer in Ontario
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    June 2023 (Anticipated)
    Primary Completion Date
    June 2025 (Anticipated)
    Study Completion Date
    June 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    The Hospital for Sick Children
    Collaborators
    Women's College Hospital, Ottawa Hospital Research Institute

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The treatments that aim to cure cancer in children can lead to "late effects" such as second cancers and heart disease. Screening tests can help find late effects, but most adult survivors of childhood cancer do not complete these tests. These survivors are at risk for harm that can be prevented. We have developed a program called ONLOOP to remind survivors in Ontario, Canada to get the screening tests they need. ONLOOP reminds survivors who are at higher risk for heart disease, breast cancer, and/or colorectal cancer to complete their echocardiograms, mammograms and breast MRIs, and/or colonoscopies. The goal of this clinical trial is to find out how well ONLOOP helps adult survivors of childhood cancer complete their screening tests. We also want to see if it could be turned into a long-term program in Ontario. Eligible survivors will be randomly assigned to either receive intervention materials or continue with usual care for 13 months before receiving intervention materials. The intervention includes usual care plus these ONLOOP materials: Study invitation letter and invitation reminder Those who sign up for ONLOOP will receive personalized health information and a screening reminder. Survivors will receive information about: their cancer treatment their risk(s) for late effects the screening tests they should do Survivors' primary care providers will be provided with the same health information provided to participants in (2)

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Survivorship, Cancer, Heart Diseases, Secondary Cancer, Colorectal Cancer, Breast Cancer
    Keywords
    Surveillance, Guideline-recommended surveillance, Implementation science, Reminder system, Intervention

    7. Study Design

    Primary Purpose
    Screening
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    900 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Intervention
    Arm Type
    Experimental
    Arm Description
    Usual care plus ONLOOP program materials: Study invitation letter and invitation reminder 5 weeks later For those who sign up: receipt of a personalized health toolkit and then a screening reminder 6 months later Engagement of primary care provider through an introductory letter and then a reminder letter sent 6 months later
    Arm Title
    Delayed Intervention
    Arm Type
    Other
    Arm Description
    Survivors will receive usual care for 13 months after study invitation packages are mailed out to the intervention arm. At that point, survivors in this group will also receive the study invitation package.
    Intervention Type
    Behavioral
    Intervention Name(s)
    ONLOOP program
    Intervention Description
    Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
    Primary Outcome Measure Information:
    Title
    Completion of guideline-recommended surveillance tests
    Description
    Proportion of survivors who complete one or more of the guideline-recommended cardiac, breast or colon surveillance tests (echocardiography, mammogram and breast MRI, colonoscopy) during the 12 months after study cohort randomization
    Time Frame
    12 months
    Secondary Outcome Measure Information:
    Title
    Completion of guideline-recommended surveillance tests
    Description
    Proportion of survivors who complete one or more of the guideline-recommended cardiac, breast or colon surveillance tests (echocardiography, mammogram and breast MRI, colonoscopy) during the 24 months after study cohort randomization
    Time Frame
    24 months
    Title
    Completion of each type of surveillance test
    Description
    Proportion of survivors who complete each type of surveillance test (among those eligible for the test)
    Time Frame
    12 months, 24 months
    Title
    Completion of all guideline-recommended surveillance tests
    Description
    Proportion of survivors who are fully up-to-date according to surveillance guidelines
    Time Frame
    12 months, 24 months
    Title
    Visits to primary care professionals and cancer specialists
    Description
    Number of outpatient visits to primary care professionals and to cancer specialists
    Time Frame
    12 months, 24 months
    Title
    Use of other healthcare services
    Description
    Rates of emergency department visits and/or hospitalizations to understand impact on health system resources
    Time Frame
    12 months, 24 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Survivors of childhood cancer who are currently aged 18 and older Diagnosed with cancer before age 18 between 1986-2017 At least 5 years from most recent childhood cancer event (latest of primary diagnosis, relapse, or second cancer before age 18) Treated at one of Ontario's five specialized childhood cancer programs Received radiation and/or anthracycline treatment that increased the survivor's risk of cardiomyopathy, breast cancer, and/or colorectal cancer Overdue for guideline-recommended surveillance by ≥6 months (mammogram and breast MRI, colonoscopy, and/or echocardiogram) Exclusion Criteria: Was not diagnosed or was not fully treated at one of Ontario's five pediatric cancer centres Developed a second cancer or relapse of their primary cancer after age 18 Not currently living in Ontario or address deemed ineligible by Ontario Health Opted out of a similar Ontario Health program (eg, the Ontario Breast Screening Program) Previously opted out of receiving invitations for Ontario Health research studies or similar communications
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Emily Lam, MSc
    Phone
    416-813-1076
    Email
    emily.lam@sickkids.ca
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Paul Nathan, MD, MSc
    Organizational Affiliation
    The Hospital for Sick Children
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Noah Ivers, MD, PhD
    Organizational Affiliation
    Women's College Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    ONLOOP Trial: Evaluating a New Surveillance and Support System for Survivors of Childhood Cancer in Ontario

    We'll reach out to this number within 24 hrs